Phibro Animal Health (NASDAQ:PAHC) Price Target Raised to $22.00 at Barclays

Phibro Animal Health (NASDAQ:PAHC) had its price target hoisted by equities researchers at Barclays from $20.00 to $22.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has an “underweight” rating on the stock. Barclays‘s price target would indicate a potential downside of 7.13% from the company’s current price.

Several other research analysts also recently commented on PAHC. Morgan Stanley lifted their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 17th. StockNews.com cut Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $21.00.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $23.69 on Monday. The company has a market capitalization of $959.45 million, a price-to-earnings ratio of 49.35, a PEG ratio of 0.53 and a beta of 0.52. The business has a 50 day moving average of $21.90 and a 200 day moving average of $21.68. The company has a debt-to-equity ratio of 2.99, a current ratio of 3.20 and a quick ratio of 1.69. Phibro Animal Health has a 1-year low of $10.03 and a 1-year high of $25.98.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.14. Phibro Animal Health had a net margin of 1.75% and a return on equity of 25.35%. On average, sell-side analysts predict that Phibro Animal Health will post 1.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP purchased a new stake in Phibro Animal Health in the 3rd quarter worth approximately $70,000. nVerses Capital LLC bought a new position in shares of Phibro Animal Health during the third quarter valued at approximately $70,000. China Universal Asset Management Co. Ltd. lifted its stake in Phibro Animal Health by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock worth $88,000 after acquiring an additional 1,522 shares during the period. New York State Teachers Retirement System boosted its holdings in Phibro Animal Health by 16.7% in the fourth quarter. New York State Teachers Retirement System now owns 5,428 shares of the company’s stock valued at $114,000 after acquiring an additional 775 shares in the last quarter. Finally, CWM LLC increased its position in Phibro Animal Health by 190.8% during the 3rd quarter. CWM LLC now owns 6,363 shares of the company’s stock valued at $143,000 after purchasing an additional 4,175 shares during the period. Hedge funds and other institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.